Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHA:603207)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Pharmaceuticals	474.58M	471.87M	456.89M	401.77M	361.23M
Pharmaceuticals Growth	0.57%	3.28%	13.72%	11.22%	6.37%
Total	474.58M	471.87M	456.89M	401.77M	361.23M
Total Growth	0.57%	3.28%	13.72%	11.22%	6.37%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
East China	172.02M	-	169.45M	150.57M	146.82M
East China Growth	-	-	12.54%	2.55%	-
North China	65.95M	-	70.16M	60.86M	51.28M
North China Growth	-	-	15.27%	18.68%	-
South China	72.25M	-	60.50M	53.70M	47.76M
South China Growth	-	-	12.67%	12.44%	-
Southwest	57.18M	-	65.62M	52.26M	39.85M
Southwest Growth	-	-	25.56%	31.16%	-
Central China	45.11M	-	43.53M	36.06M	32.33M
Central China Growth	-	-	20.72%	11.54%	-
Northeast	42.68M	-	45.96M	45.88M	38.84M
Northeast Growth	-	-	0.17%	18.11%	-
Northwest	18.80M	-	14.87M	12.14M	8.95M
Northwest Growth	-	-	22.50%	35.58%	-
Overseas	239.22K	-	-	-	-
Macao, China	-	-	76.90K	-	-
Unallocated	-	-	-13.70M	-10.16M	-5.24M
Total	474.23M	-	456.46M	401.29M	360.59M
Total Growth	-	-	13.75%	11.29%	6.18%

Source: S&P Global Market Intelligence.